RenovoRx (Nasdaq: RNXT) this week said its RenovoCath drug-delivery device was used for the first time in its post-marketing registry study.
The case was performed at the University of Vermont Cancer Center in the company’s PanTheR Post-Marketing Registry Study.
The multi-center registry is designed to assess long-term safety and survival outcomes in patients with solid tumors treated using RenovoCath. Baptist Health Miami Cancer Institute and the University of Pittsburgh Medical Center have joined Vermont as clinical sites, with procedures expected to begin soon.
Related: Medtronic Hugo surgical robot meets endpoints in hernia repair study
Principal investigators include Dr. Conor O’Neill at Vermont, Dr. Ripal Gandhi at Baptist Health, and Dr. Paula Novelli at UPMC.
RenovoCath is a patented, FDA-cleared drug-delivery device intended for the isolation of blood flow and delivery of fluids, including diagnostic or therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications such as arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
“We are pleased to be the first site to initiate cancer treatment delivery by RenovoCath in the important PanTheR registry study,” O’Neill said. “This study provides a crucial opportunity to evaluate how RenovoCath can improve drug-delivery in patients diagnosed with solid tumors, while potentially, and importantly, improving survival and quality of life outcomes. By contributing to this registry study, we aim to generate meaningful real-world data that can guide future treatment decisions for patients with difficult-to-treat cancers.”
RenovoRx said participating centers will purchase RenovoCath devices for use in the study and that additional updates will follow as enrollment expands.
